# Attempt 9: explicit localized/mild C30 clarification

Run `9836179b-d3ae-4f03-9521-b5720ef8b8f4` used the same v17 graph, v2 clinical policy, prompt hash and corpus as attempt 8. The input was deliberately different: the patient update explicitly said the rash was **still only on the forearms**, the itch was **mild and did not affect sleep**, and there was **no face/eye/genital involvement, increasing pain or pus**. This is a clarified-input test, not evidence that the original unclarified case now passes.

The run released a model-reviewed **Self care** answer in **79.454 seconds** after **six calls and one repair**. The server patient reply occurred at **79.421 seconds**; no early action or question was emitted. Root reported browser reply/finish at **79.47 seconds**. Estimated cost was **$0.508419**, bringing the nine-attempt GUI subtotal to **$3.827889**.

The initial review required same-day timing and an unavailable-service fallback for future worsening or infection signs. The repaired response supplied those and was accepted by all seven judge criteria. Explicit localization now supports describing the rash as confined; the vital-sign prose also correctly preserves uncertainty about whether temperature was measured.

## What the acceptance does not establish

- The judge's repair instruction said **"Counsel may help coordinate"**. The final answer changed that to **"Counsel can help coordinate"**, and the final ownership review accepted it because there was no promise of clinician acceptance. That still implies a capability not verified by this stubbed system. This possible capability overstatement originated partly in the reviewer, not solely in the draft model.
- The final instruction **"Seek emergency care for trouble breathing or facial/throat swelling"** still groups isolated facial swelling with airway concerns. It is not identical to attempt 8's blanket **911** instruction, so the verdicts are not a strict identical-text contradiction. The scope of this safety-net threshold nevertheless remains a clinical-policy review issue, not a settled pass inferred from one machine review.
- One structured red-flag row calls **"Extent of body surface involved beyond forearms"** `reported`, quoting **"The rash is still only on my forearms"**. At minimum this is an ambiguous label/status combination that could mislead a downstream fact consumer. The narrative is clearer than this row; the final judge did not flag it.
- Evidence is still a consumer summary and agent-compiled ED reference material. Machine acceptance of those claims does not establish primary-guideline coverage, completeness of all clinical claims, or prospective clinician validation.

The released answer is a useful observed improvement for this clarified input. It is not a generalization result, a repair of the unresolved C50 failures, or evidence that the original C30 now reliably yields a timely final answer.
